Skip to main content
Equibles
AVTX logo

AVTX · Avalo Therapeutics, Inc.

Track AVTX — free

Use AVTX with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about AVTX

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$19.60 -0.46 (-2.27%)
Russell 2000 member Rebalance outlook locked
Market Cap
$1.10B
Shares
53.63M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$20.05 Open$20.47 Day$19.91–20.57 52W close$9.02–22.87 Avg vol 30d775K Short int13.1M · 24.4% float · 20.2d Short vol73% DataDec 2023–Aug 2026 Filing10-Q · Aug 6

Raw chart and full-history price indicators begin at the captured split on Dec 29, 2023; bars on opposite sides are not compared.

Up next

FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Aug 6, 2026

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Buy Momentum Very Strong Sentiment Neutral Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 14.5 · calm Equity put/call 0.39
Technical
price trend
Buy
50 / 200-day cross No cross
Price vs 200-day avg +19%
above
Price vs 50-day avg +7%
above
RSI (14) 55
neutral
MACD trend Positive
52-week position 80%
mid-range
Momentum
relative strength
Very Strong
1-month return +3%
trailing
6-month return +16%
trailing
YTD return +10%
this year
Relative strength +1%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $19 › 200d $17 — 50d above 200d
Institutional flow Accumulating
+26% holders QoQ · +53 funds added
Insider flow Distributing
Net -$52.0K over 90 days · 100% sells
Short interest Rising
24.41% of float · ▲ +1.1% MoM · 20.2 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
127 holders — near 3-yr high, broad support
Squeeze score 78
high risk · 0–100
Fundamentals
Strong
Revenue growth +2312%
Y/Y
EPS growth +72%
Y/Y
Free cash flow $-51.6M
Balance sheet $480.1K
net cash
Quant / Vol
risk profile
Very High
Volatility 89%
annualized · 1-yr
Max drawdown −44%
past year
ATR 5.3%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Buy
0 · 3 · 3
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+19% Bullish
Price vs 50-day avg
+7% Bullish
RSI (14)
55 Neutral
MACD trend
Positive Bullish
52-week position
80% Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross) No cross
50d $19 › 200d $17 — 50d above 200d
Institutional flow Accumulating
+26% holders QoQ · +53 funds added
Insider flow Distributing
Net -$52.0K over 90 days · 100% sells
Short interest Rising
24.41% of float · ▲ +1.1% MoM · 20.2 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
127 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $9 Now $20 · 80% Range high $23
vs 200-day avg +19% vs 50-day avg +7%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Net cash used in operating activities $51.5M Year ended December 31, 2025 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
AVTX
Avalo Therapeutics, Inc.
this stock
$1.10B +10.4% +2312.3% — 24.4%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $137.30B +20.8% +46.2% 31.6 1.6%
REGN
Regeneron Pharmaceuticals, Inc.
 $81.27B +4.6% +20.8% 19.6 2.3%
ARGX
Argenx SE
 $65.12B +25.9% — — 1.9%
CSLLY
Csl Ltd
 $59.92B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
127
% held
133.6%
Net QoQ
+37.4M sh
Top holder
FMR LLC
Held Float
View
Held by Funds
Fund positions
96
View
Short & Settlement
Short Interest Rising
Shares short
13.1M
Days to cover
20.2d
Change
+142.5K sh
View
Short Volume
Short vol %
73%
As of
Aug 28, 2026
Short Total
View
Fails to Deliver
FTD shares
1
Value
$19
As of
Jul 31, 2026
View
Off-Exchange
Off-exchange %
41.8%
Week of
Jul 20, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net selling
Net (90d)
-$52.0K
Buyers / Sellers
0 / 1
Buyers Sellers
View
Financials
Financials
Revenue (FY)
$59.0K
Net income (FY)
$-78.3M
EPS diluted
$-5.84
View
Filings
SEC Filings
Latest
8-K
Filed
Aug 6, 2026
This year
16
View
Proposed Sales
Value
$622.2K
Shares
31.0K
Filed
Aug 18, 2026
View
Exempt Offerings
Offering
$200.0M
Filed
Apr 9, 2024
View

Performance

Raw-price comparisons begin at the captured split on Dec 29, 2023; windows that need an earlier baseline remain unavailable.

5D 20D 120D MTD YTD
AVTX +1.2% +3.4% +15.8% +9.9% +10.4%
SPY +1.1% +4.0% +14.7% +3.2% +13.1%
vs SPY +0.1% -0.6% +1.2% +6.6% -2.7%
Key facts CIK 1534120 CUSIP 05338F306 13F (30d) 129 filings 120 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)